Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 Trial
Jonathan Strosberg(Moffitt Cancer Center), Matthew H. Kulke(Brigham and Women's Hospital), Edward M. Wolin(University of Kentucky), Martyn Caplin(The Royal Free Hospital), Thomas Thevenet(Moffitt Cancer Center), David Bushnell(University of Iowa), Andrew Hendifar(Cedars-Sinai Medical Center), Inés Margalet(Dana-Farber Cancer Institute), Richard P. Baum(Moffitt Cancer Center), Maribel Lopera Sierra(Moffitt Cancer Center), Timothy J. Hobday(Mayo Clinic), Pamela L. Kunz(Dana-Farber Cancer Institute), Kjell Öberg(Moffitt Cancer Center), Eric P. Krenning(Erasmus MC), Beth Chasen(The University of Texas MD Anderson Cancer Center), Philippe Ruszniewski(Institut de Recherche contre les Cancers de l’Appareil Digestif)
Cited by 388
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
|Neuroendocrinology|2012|869
The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors
|Endocrine Reviews|1991|814